AAA+ proteins, a superfamily of ATPases associated with diverse cellular activities, play essential roles in energy-dependent remodeling of macromolecular complexes such as proteins, DNA, and RNA. Their function hinges on a conserved 250-amino acid AAA+ domain that typically forms oligomeric structures critical for processes including protein quality control, DNA replication, and cytoskeletal dynamics. Dysregulation of these molecular machines is linked to severe human pathologies, including neurodegenerative diseases and cancer progression. Despite their biological significance, therapeutic targeting of AAA+ proteins has remained challenging due to the high structural conservation across the family, dynamic conformational changes during catalysis, and the hydrophilic nature of their ATP-binding sites.

Traditional drug discovery efforts relying on broad-spectrum compound screens have yielded only a limited number of inhibitors with poor selectivity. Inhibitors binding allosteric sites may disrupt complex assembly or protein stability, leading to off-target effects. Moreover, the scarcity of high-resolution structures for many AAA+ complexes hampers rational design. Targeting the ATP-binding site using competitive nucleotide analogs offers a promising alternative—providing potential for both specificity and cross-family applicability. However, achieving this remains difficult because of sequence conservation and conformational flexibility in the active site.

Recently, Tarun Kapoor’s group pioneered a chemical genetics strategy known as RADD (Resistance Analysis During Design), which enables the development of selective inhibitors by exploiting subtle differences in the ATP-binding pocket. The approach identifies a “variability hotspot”—a cluster of four amino acids in the active site whose mutation can alter inhibitor sensitivity without affecting enzymatic activity. By introducing silent mutations at these positions, researchers can screen for compounds that bind the wild-type site but not the mutated one, thereby identifying highly specific ligands.CD30 Antibody In stock

In a recent study, Cupido et al.CD116 Antibody In stock extended this concept to katanin, a microtubule-severing AAA+ complex.PMID:34996900 Instead of starting with an inhibitor, they first engineered a katanin variant with a strategically placed cysteine residue—a “bump-and-hole” modification—without compromising function. This allowed them to design ASPIR-1, a covalent, nucleotide-competitive inhibitor that selectively binds the mutant enzyme with subnanomolar potency (<50 nM). Upon exposure to ASPIR-1, cells exhibited phenotypes identical to those seen after genetic depletion of katanin, confirming rapid and specific inhibition in vivo. Crucially, the same inhibitor was shown to effectively target homologous AAA+ proteins involved in membrane remodeling (VPS4B) and DNA repair (FIGL1), suggesting a shared binding mode across the superfamily. This opens the door to creating analogous inhibitor-sensitive variants in other AAA+ proteins simply by introducing a cysteine at the equivalent position. This work establishes a powerful platform for dissecting the functional roles of individual AAA+ isoforms, transient protein complexes, and disease-causing mutations in real time. It also provides a robust method for detecting off-target effects during drug development and accelerates the creation of precision therapeutics. With its cost-efficiency and scalability, the RADD-based approach holds significant promise for treating rare diseases caused by ATP-pocket mutations through protein-stabilizing drugs.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Hypochlorite (ClO⁻) plays a significant role in biological systems, particularly in immune responses and oxidative stress-related diseases. Its dysregulation has been linked to neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, cerebral ischemia, and cancer. Accurate detection of ClO⁻ is therefore crucial for both diagnostic and therapeutic applications. Traditional analytical methods like electrochemical analysis, colorimetry, and chromatography often require complex procedures and are typically limited to organic or mixed solvents, which restricts their utility in aqueous environments. To address this limitation, the development of rapid, sensitive, and selective fluorescent sensors for ClO⁻ in water is highly desirable.

In this study, a novel fluorescent sensor based on thiophene-cyanostilbene Schiff-base (TCS) was designed and synthesized. The sensor leverages the aggregation-induced emission (AIE) effect, enabling strong fluorescence in aqueous media. TCS exhibits excellent photostability and high quantum yield in THF-H₂O mixtures with 90% water content, where the fluorescence intensity increases significantly due to restricted intramolecular rotation upon aggregation. Upon exposure to ClO⁻, the fluorescence of TCS is dramatically quenched, while other cations and anions show negligible interference, demonstrating exceptional selectivity.

The detection limit of TCS for ClO⁻ reaches as low as 3.MAGEB4 Antibody supplier 2 × 10⁻⁸ M, making it one of the most sensitive probes reported to date.1082744-20-4 Synonym Mechanistic investigations using FT-IR, ¹H NMR, MS, and Job’s plot confirmed that ClO⁻ oxidizes the sulfur atom in the thiophene ring to form a sulfone group. This structural change disrupts the π-conjugation and enhances non-radiative decay pathways, resulting in fluorescence quenching. DFT calculations further supported this mechanism by showing a significant increase in the HOMO-LUMO energy gap after oxidation, consistent with the observed blue shift in emission.

The sensor was successfully applied to detect ClO⁻ in real-world samples, including commercial disinfectants, with results closely matching those obtained via iodometric titration.PMID:35034599 Additionally, TCS demonstrated outstanding performance in live-cell imaging using MCF-7 cells. Confocal laser scanning microscopy revealed bright fluorescence in cells pre-incubated with TCS, which was almost completely suppressed upon addition of ClO⁻, confirming its ability to trace intracellular ClO⁻ levels dynamically. No significant cytotoxicity was observed at working concentrations, indicating good biocompatibility.

These findings highlight the potential of TCS as a powerful tool for both in vitro assays and in vivo monitoring of hypochlorite. Its high sensitivity, excellent selectivity, low detection limit, and compatibility with living systems make it a promising candidate for biomedical applications, environmental monitoring, and clinical diagnostics.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Product Name :
G1/S-specific cyclin-D2